test

A Phase I, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects with Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications

Conditions

Breast - Female | Colon | Lung | Melanoma, skin | Ovary | Rectum | Stomach

What is the purpose of this trial?

This is a Phase 1, open-label, dose-escalation trial of MSB0010718C [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in subjects with selected tumor indications.


Participation Guidelines

Age:
Gender:

Click here for detailed information about who can participate in this trial.


Sponsor:
EMD Serono, Inc.
Dates:
05/05/2014
Last Updated:
Study HIC#:
1309012779